PSY9 BUDGET IMPACT OF THE USE OF OROS® HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM
The budget impact of introducing OROS ® hydromorphone once-daily, a novel therapy for treating patients with severe chronic cancer and non-cancer pain, was determined in the German health care system. METHODS: The perspective of the social health insurance over a one-year time horizon was adopted. An Excel ® based hypothetical budget impact model calculating the cost consequences of using strong opioids (WHO step III) was developed. The model accounts for the costs of opioids, breakthrough pain and adverse events. Patient numbers are calculated using epidemiological data from the literature; adverse event rates are based on literature. Comparators included sustained-release (SR) morphine (twice-daily), controlled-release (CR) oxycodone (twice-daily), hydromorphone (twice-daily), transdermal fentanyl and transdermal buprenorphine. Initial prescription share of OROS ® hydromorphone was 2.4% (October 2007 MAT). This share was hypothetically extended to 8%. It was assumed that this increase in prescription of OROS ® hydromorphone is gained by switching patients from their previous medication to OROS ® hydromorphone (proportionally to the prescription share of the comparator at start). Titration and maintenance dosing schemes taken from previous analyses are used to model the switch. Morphine equivalence of hydromorphone was chosen according to SmPC. RESULTS: The number of patients treated was estimated to be 882,347 per year. The model predicted that the introduction of OROS ® HM would lower the per patient drug cost from €684.28 to €679.52 (2008 public prices). The model also predicts that as the use of OROS ® HM increases, the total budget for strong opioids decreases. If the prescription share of OROS ® HM increased to 8% the total budget for strong opioids would decrease by €4,199,327. CONCLUSIONS: Our analysis suggests that under current circumstances the use of OROS ® hydromorphone to treat patients with severe chronic pain will reduce the overall budget spent on strong opioids. 
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